Biosimilars Series: Stakeholder Analysis

Publication Date	August 2008
Publisher	Datamonitor
Product Type	Report
Pages	98
ISBN Number	not applicable
Product Code	DAT13073

Price

£3,800.00
approximately: $5,553 | €4,165

PDF

PRINT £3,850 ($5,626 | €4,219)

Order above formats by FAX

Summary

Introduction

Although Europe is leading the way, the biosimilar industry is very much in its infancy, with the perception of key decision makers critical to the initial rate of uptake. The opinion of key stakeholders, and the influence they wield, will therefore inform the strategy of both the branded and biosimilar contingents, in what is likely to become a battle to gain trust.

Scope

An overview of the key drivers and resistors to biosimilar use.
An outline of the key stakeholders in Europe and the US, and relative influence they have.
An insight into the opinion of payers, physicians and hospital pharmacists, regarding biosimilar use.
An understanding of how the industry will develop, and the strategies to be employed by the pro and anti biosimilar factions.

Highlights

Biologics use is set to grow, at a rate that far outstrips that of small molecule drugs. The considerably greater cost of biologics will therefore combine with increased utilization to put payers under pressure to promote biosimilar use.

Due to the complexity of biologic drugs, there are greater concerns regarding biosimilar safety and efficacy compared with standard generics, which are likely to only be alleviated following time on the market. Consequently, initial uptake will be greatly influenced by the perceptions of key stakeholders.

The opinion of physicians is considered important by both branded and biosimilar companies, and in Europe this group currently holds the most power. Although motivated to promote generics, payers and pharmacists to an extent, often defer to physicians in Europe, although there is evidence this is not the case in the US.

Reasons to Purchase

Understand which drugs are subject to biosimilar erosion in Europe now, and going forward.
Understand who the key stakeholders are and the influence they have on biosimilar uptake.
Gain an insight into how the biosimilar industry will develop, and the strategies companies will employ to promote or resist uptake.

Content

CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the report
- Key findings
CHAPTER 2 OVERVIEW OF THE BIOSIMILARS MARKET LANDSCAPE
- Who are likely to be the key players in the biosimilar industry?
- Large generics players to be at forefront of biosimilar wave
- The fragmented nature of the European market may hinder uptake
- The price of biosimilars
- Will branded manufacturers compete on price?
- Second wave of biosimilars likely to be more profitable
- Confidence in the EMEAs approval pathway for biosimilars
- Hospital versus retail setting for European biosimilar uptake
- Automatic substitution versus interchangeability
- Potential UK black triangle warning has implications for interchangeability
- The stakeholder view
- Payers and pharmacists to drive biosimilar uptake
- Physicians must be on board
- Patients unlikely to have a voice on the biosimilar issue
CHAPTER 3 ISSUES IMPACTING BIOSIMILARS UPTAKE
- Drivers of biosimilar uptake
- Demographic trends point to a need to cut costs
- Some biologic drugs treat rare conditions
- Biologic drug use is on the increase
- High cost of biologics should promote biosimilar uptake
- Rising cost of healthcare in the US and growing use of tier four
- Resistors to biosimilar uptake
- The product is the process dogma will hinder biosimilar uptake
- Subtle structural differences in biologic drugs can have clinical consequences
- Heparin contamination issues
- Specialty drug distribution agreements
CHAPTER 4 US PAYER INSIGHTS
- Were a biosimilar approved, would US payers include it in their formularies?
- How much clinical data do payers require?
- Stimulation of biosimilar uptake
- Step edits and more favorable reimbursement to promote uptake
- Switching patients from branded to biosimilar drugs is a distinct possibility
- The level of biosimilar discount
- Rebates as the tool of choice for branded manufacturers
CHAPTER 5 BIOSIMILAR TEST CASE: HUMAN GROWTH HORMONE
- Testing the water with Omnitrope
- Omnitrope established Sandoz as a key biosimilar player
- The human growth hormone market is difficult to penetrate
- Tev-Tropins market presence, prior to Omnitrope launch, may have contributed to poor uptake in the US
- Branded manufacturers likely to have responded aggressively
CHAPTER 6 BIOSIMILAR TEST CASE: EPOETIN
- Biosimilar epoetin in Europe, a large lucrative market?
- The epoetin market is a closely held one
- The epoetin market is a difficult one to penetrate, as the experience of Dynepo shows
- Several biosimilar epoetins have entered the European market
- Biosimilar epoetin makes first showing in cost-conscious Germany
- Biosimilars could struggle in the UK epoetin market
CHAPTER 7 THE FUTURE FOR BIOSIMILARS
- Biosimilar G-CSF market launch imminent
- G-CSF brand choice in Europe
- Biosimilar insulin a difficult market to enter
- Analogs limit growth opportunities in more developed markets
- US payer stance on biosimilar insulin
- Product loyalty is a factor any insulin biosimilar maker must overcome
CHAPTER 8 BIBLIOGRAPHY
- Publications and online articles
- Conference literature
- Datamonitor resources
- APPENDIX
LIST OF FIGURES
- Figure1: The emerging biosimilar landscape, 2008
- Figure2: The hospital versus retail divide
- Figure3: Influence of the key stakeholders in the US and EU to promote biosimilar uptake, 2008
- Figure4: Drivers and resistors of biosimilar uptake
- Figure5: Key stakeholders in the US, and their influence on biosimilar uptake
- Figure6: Key drivers and resistors of biosimilar growth hormone uptake
- Figure7: Price of lyophilized somatropin per gram in Germany and the US in 2007, relative to that of Omnitrope
- Figure8: Key drivers and resistors of biosimilar growth hormone uptake, 2008
- Figure9: Epoetin use in the 5EU, 2007
- Figure10: Effect of biosimilar epoetin on market share in Germany, September 2006January 2008
- Figure11: Hospital epoetin use in the UK, 2008
- Figure12: Key drivers and resistors of biosimilar granulocyte-colony stimulating factor (G-CSF)uptake, 2008
- Figure13: Neulasta versus Neupogen use in the US and Europe, 200307
- Figure14: Granulocyte-colony stimulating factor (G-CSF) use in the 5EU, 2007
- Figure15: Drivers and resistors for recombinant insulin uptake, 2008
LIST OF TABLES
- Table 1: Indian companies manufacturing biosimilars in India, 2008
- Table 2: Epoetin market size in US and 5EU, 200607
- Table 3: High cost of biologic drugs in the US, 2008
- Table 4: Estimated savings following the use of biosimilar drugs
- Table 5: Omnitrope sales in the US and 5EU, 2007
- Table 6: Development and marketing of epoetin US and Europe, 2008
- Table 7: Dynepo market share in the US and 5EU, 2007
- Table 8: The retail-hospital split for epoetins in the 5EU, 2007